BLA 103705/5409

SUPPLEMENT APPROVAL

Genentech, Inc.
A Member of the Roche Group
1 DNA Way
South San Francisco, CA 94080

Attention: Stuart Heminway, Program Director
Regulatory Affairs

Dear Mr. Heminway:

Please refer to your Supplemental Biologics License Application (sBLA), dated March 25, 2013, received March 26, 2013, submitted under section 351(a) of the Public Health Service Act for Rituxan (rituximab).

We acknowledge receipt of your amendments dated April 25 and May 2, 2013.

This “Changes Being Effected” supplemental biologics application provides for a change to the WARNINGS AND PRECAUTIONS in Section 5.3 - Severe Mucocutaneous Reactions of the package insert to add information regarding the variable onset of severe mucocutaneous reactions, including onset on the first day of Rituxan exposure.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Reference ID: 3306035
Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Philantha Bowen, Senior Program Management Officer, at (301)796-2466.

Sincerely,

*See appended electronic signature page*

Robert C. Kane, M.D.
Deputy Director for Safety
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT C KANE
05/09/2013

Reference ID: 3306035